Sort
4,870 grants matching “glp 1”
Novel PDE Inhibitors for Treatment of Cognitive Dysfunction in Schizophrenia
$964,465Lawrence Paul Wennogle · Intra-Cellular Therapies, Inc. · R44 · FY2009 · MH
HLS- Factor XII Inhibitor for Surface Initiated Thrombosis
$963,088Erik Ian Tucker · Aronora, Inc. · R44 · FY2018 · HL
Novel antioxidants for periodontal disease
$961,860Inotek Pharmaceuticals Corporation · R44 · FY2003 · DE
Long Acting Native GLP-1 formulations for Type 1 Diabetes
$960,879Elijah M. Bolotin · Pharmain Corporation · R44 · FY2008 · DK
Closed-loop neuroelectric control of emesis and gastric motility
$960,848Charles Christopher Horn · University Of Pittsburgh At Pittsburgh · U18 · FY2017 · TR
Renal Therapeutic Angiogenesis Using the Novel Biologic ELP-VEGF
$960,794Gene Leflore Bidwell · Leflore Technologies, Llc · R42 · FY2023 · DK
Development of patented tricyclic pyrones molecules for the treatment of Alzheimerâs Disease
$960,706Xinmin Simon Xie · Afasci, Inc. · R44 · FY2018 · AG
Riluzole Prodrugs for Melanoma and ALS
$960,120Allen Bernard Reitz · Fox Chase Chemical Diversity Center, Inc · R44 · FY2013 · CA
Cell Based Therapy for Treatment of Traumatic Brain Injury
$959,795Robert William Mays · Athersys, Inc. · U44 · FY2013 · NS
An Improved Method of Delivering a Sclerosing Agent for the Treatment of a Malignant Pleural Effusion.
$959,737Glenn W Laub · Tdl Innovations, Llc · R44 · FY2020 · CA
Riluzole Prodrugs for Melanoma and ALS
$959,604Allen Bernard Reitz · Fox Chase Chemical Diversity Center, Inc · R44 · FY2014 · CA
Long Acting Native GLP-1 formulations for Type 1 Diabetes
$959,053Elijah M. Bolotin · Pharmain Corporation · R44 · FY2009 · DK
Preclinical Alzheimers Disease Drug Development of Novel MAPK Inhibitors
$958,225D. Martin Watterson · Northwestern University At Chicago · U01 · FY2012 · AG
A Novel Engineered Probiotic for the Prevention of Clostridium Difficile Infection
$957,796Gary Fanger · Rise Therapeutics, Llc · R44 · FY2020 · AI
Therapeutic Thrombin Analogs
$957,597Erik Ian Tucker · Aronora, Inc. · R44 · FY2015 · HL
A Randomized Phase 2A Clinical Trial Pioneering the Utility of an eNAMPT-Reducing Therapy in ARDS/VILI: the PUERTA Trial
$957,594Joe G. N. Garcia · Aqualung Therapeutics Corp. · R44 · FY2024 · HL
Polynitroxylated Pegylated Hemoglobin for Traumatic Brian Injury Resuscitation
$957,098Carleton Hsia · Synzyme Technology, Inc. · U44 · FY2013 · NS
Twice-Weekly Subcutaneous Liposome Chelator to Treat Transfusional Iron Overload
$956,715Mark Eamon Hayes · Zoneone Pharma, Inc. · R44 · FY2016 · HD
A Novel Probiotic for the Treatment of Sjogren's Syndrome
$956,644Gary Fanger · Rise Therapeutics, Llc · R44 · FY2019 · DE
A Novel Immunological-Directed Synthetic Biology-Based Drug for the Treatment of Multiple Sclerosis
$956,049Christian Furlan Freguia · Rise Therapeutics, Llc · R44 · FY2024 · AI
Biobehavioral Studies of Obesity, Weight loss and Recidivism
$955,976Ranganath Muniyappa · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2023 · DK
Novel Vaccine Technology for Chikungunya
$954,393Scott C Weaver · University Of Texas Med Br Galveston · R01 · FY2013 · AI
Factor XII Inhibitor for Surface Initiated Thrombosis
$953,492Erik Ian Tucker · Aronora, Inc. · R44 · FY2022 · HL
Commercial and Regulatory Development of an Enhanced Performance Hemodialysis Access Graft
$953,444Andrew Marshall · Healionics Corporation · SB1 · FY2024 · HL
Development of Novel Therapeutic Agents for Norovirus Infection
$952,801Kyeong-Ok Chang · Kansas State University · U01 · FY2012 · AI